{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=post-radiation+therapy+temozolomide&page=4", "query": { "intervention": "post-radiation therapy temozolomide", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 175, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=post-radiation+therapy+temozolomide&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=post-radiation+therapy+temozolomide&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T08:58:45.941Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00089427", "title": "IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Oligoastrocytoma" ], "interventions": [ { "name": "IL13-PE38QQR", "type": "DRUG" }, { "name": "Surgery for placement", "type": "PROCEDURE" }, { "name": "Radiation therapy", "type": "PROCEDURE" }, { "name": "Temozolomide with radiation therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2004-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-07-04", "last_synced_at": "2026-10-14T08:58:45.941Z", "location_count": 6, "location_summary": "San Francisco, California • Charlotte, North Carolina • Durham, North Carolina + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00089427" }, { "nct_id": "NCT02344355", "title": "A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "Ascorbic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Bryan Allen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2017-03-13", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-14T08:58:45.941Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02344355" }, { "nct_id": "NCT00792012", "title": "A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Hypofractionated Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2005-11", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2017-03-27", "last_synced_at": "2026-10-14T08:58:45.941Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00792012" }, { "nct_id": "NCT01473901", "title": "A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "BKM120 + temozolomide", "type": "DRUG" }, { "name": "BKM120 +temozolomide with/without radiotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2011-12-30", "completion_date": "2017-05-17", "has_results": false, "last_update_posted_date": "2020-12-09", "last_synced_at": "2026-10-14T08:58:45.941Z", "location_count": 3, "location_summary": "Fayetteville, Arkansas • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01473901" }, { "nct_id": "NCT06805305", "title": "DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma (GBM)" ], "interventions": [ { "name": "DOC1021", "type": "BIOLOGICAL" }, { "name": "Tumor resection", "type": "PROCEDURE" }, { "name": "Temodar (Temozolomide)", "type": "DRUG" }, { "name": "SOC cranial radiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Diakonos Oncology Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2025-03-17", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-14T08:58:45.941Z", "location_count": 18, "location_summary": "Gilbert, Arizona • Duarte, California • Newport Beach, California + 14 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06805305" }, { "nct_id": "NCT01186406", "title": "Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Gliosarcoma" ], "interventions": [ { "name": "Gliadel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Avastin", "type": "DRUG" }, { "name": "Temodar", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2011-04", "completion_date": "2014-06-16", "has_results": true, "last_update_posted_date": "2019-02-15", "last_synced_at": "2026-10-14T08:58:45.941Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186406" }, { "nct_id": "NCT06504381", "title": "DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Glioma", "MGMT-Unmethylated Glioblastoma", "MGMT-Methylated Glioblastoma" ], "interventions": [ { "name": "DB107-RRV", "type": "GENETIC" }, { "name": "DB107-FC", "type": "DRUG" }, { "name": "Radiation Therapy (RT)", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" }, { "name": "Surgical resection", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-01-08", "completion_date": "2042-01-31", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-14T08:58:45.941Z", "location_count": 5, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06504381" }, { "nct_id": "NCT01478854", "title": "Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2011-12-27", "completion_date": "2018-04-25", "has_results": true, "last_update_posted_date": "2019-06-13", "last_synced_at": "2026-10-14T08:58:45.941Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01478854" }, { "nct_id": "NCT00304031", "title": "Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "Concurrent temozolomide", "type": "DRUG" }, { "name": "Concurrent radiation therapy", "type": "RADIATION" }, { "name": "100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle", "type": "DRUG" }, { "name": "75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 1173, "start_date": "2006-01", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2020-06-09", "last_synced_at": "2026-10-14T08:58:45.941Z", "location_count": 341, "location_summary": "Fairbanks, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 240 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Auburn", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00304031" }, { "nct_id": "NCT02864368", "title": "Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "5-day TMZ", "type": "DRUG" }, { "name": "21-day TMZ", "type": "DRUG" }, { "name": "PEP-CMV: Component A", "type": "BIOLOGICAL" }, { "name": "Tetanus-Diphtheria booster", "type": "DRUG" }, { "name": "Tetanus Pre-Conditioning", "type": "DRUG" }, { "name": "PEP-CMV: Component B", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Eric Thompson, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2016-12-07", "completion_date": "2020-06-15", "has_results": true, "last_update_posted_date": "2022-06-09", "last_synced_at": "2026-10-14T08:58:45.941Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02864368" } ] }